R&D Day 2023
Successful Research & Development Day
We are thrilled about our first-ever Research & Development (R&D) Day at our Hørsholm HQ in late May. The event was a resounding success, featuring talks by Evaxion scientists and collaborators sharing previously unreleased preclinical data.
More specifically, the spotlight was on Evaxion’s proprietary Antigen Presenting Cell (APC) targeting technology utilizing a genetic immune adjuvant to improve vaccine response across multiple AI-predicted antigens and diseases. Alongside our own researchers and scientists, we were also joined by our collaborators from Pantherna, that presented how to improve mRNA and LNP delivery technologies for vaccines.
We have captured the highlights from the R&D Day in a series of perceptive videos where our exceptional team presents comprehensive details about our proprietary APC-targeting technology. Take a look below.
Stine Friis and Marina Barrio-Calvo
Introduction to Evaxion's APC targeting DNA vaccine technology
Watch Stine Friis, Director of Immuno-Oncology and Preclinical Development, and Marina Barrio-Calvo, Senior Associate in Immuno-Oncology, give an introduction to Evaxion's APC targeting DNA vaccine technology during our R&D Day.
APC targeting and cancer vaccines
Watch Marina Barrio-Calvo, Senior Associate in Immuno-Oncology, give a presentation on APC targeting and cancer vaccines.
Stine Friis and Ansgar Santel
Pantherna and Evaxion mRNA-LNP vaccine
Watch Pantherna's Ansgar Santel, Head of Translational Research, and Evaxion's Stine Friis, Director of Immuno-Oncology and Preclinical Development, present how the collaboration between the two companies can enhance the delivery of cancer-specific antigens with CCL19 as APCt unit.
APC targeting and viral vaccines
In this video, Gry Persson, Project Manager for Infectious Diseases and Vaccine Discovery, presents how the technology used for cancer-specific vaccines could be used for viral vaccines as well.
APC targeting and bacterial vaccines
Watch Sophie Schussek, Project Manager for Infectious Diseases and Vaccine Discovery, explain how APC targeting affects the development of bacterial vaccines.